Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

spartalizumab 2pembrolizumab 2trastuzumab deruxtecan 1trametinib 1siremadlin 1sargramostim 1resiquimod 1poly ICLC 1pegfilgrastim 1nazartinib 1liposomal doxorubicin 1lenvatinib 1eribulin 1enzalutamide 1canakinumab 1Vaccines 1TKM-080301 1Quality of Life 1Prednisone 1Prednisolone 1Patient Reported Outcome Measures 1Panobinostat 1Molecular Diagnostic Techniques 1MORAb-202 1LCL161 1Ipilimumab 1Immunotherapy 1Imatinib Mesylate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × siremadlin × Breast × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡